
GeneDx Faces Securities Lawsuit After Fabric Genomics Impairment
A 49% collapse in GeneDx Holdings stock following a disastrous Q1 2026 earnings report has triggered a securities class action investigation. Law firm Hagens Berman is probing whether executives misled investors regarding the profitability and integration of Fabric Genomics, an acquisition that resulted in a $31.2 million impairment charge.













.jpeg)










